Current stock page

Catalysts

TARS Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

TARSTarsus Pharmaceuticals, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$80.28+$3.39 (+4.41%)

Latest quote

  • Momentum
    76
  • Value
    75
  • Quality
    50
  • Risk resilience
    59
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 22, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 65/100

Momentum 76/100 and sentiment — before the next covered event.

Recent coverage
4 articles

Updated Nov 15, 2026 · Sentiment 18.38%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 76/100AIQ Edge 8/10 Strong Relative Position
Beat rate
50%
4 of 8 reported periods
Average surprise
-132.1%
Across covered historical reports
Latest result
-886.3%
Nov 3, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 3, 2026—-$1.46-$14.40-886.3%$187.83M$194.57M
Aug 6, 2026—-$0.19-$0.43-124.2%$169.65M$173.91M
May 6, 2026—-$0.40-$0.16+60.2%$149.6M$162.05M
Feb 23, 2026—-$0.10-$0.20-94.2%$144.57M$151.67M
Nov 4, 2025—-$0.35-$0.30+14.3%$144.64M$118.7M
Aug 6, 2025—-$0.33-$0.48-45.5%$113.05M$102.66M
May 1, 2025—-$0.69-$0.64+7.2%$99.11M$78.34M
Feb 25, 2025—-$0.68-$0.60+11.8%$64.45M$66.41M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
10
Buy
12-month analyst target
$109.25
+36.09% versus current price
Based on 10 analyst observations. Targets are estimates, not predictions.
Low target
$105.00
+30.79% vs latest price
Average target
$109.25
+36.09% vs latest price
High target
$116.00
+44.49% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 22, 2027

Next known earnings or reporting date.

EPS estimate-$0.28

Current analyst expectation for the upcoming report.

Revenue estimate$210.77M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score76

Where event reaction would show up first.

AIQ score65/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
10
Average target
$109.25
Target upside
36.09%
Target range
$105.00 - $116.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
2
Negative
0
zacks.com · Nov 3, 2026

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of +45.46% and +3.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

seekingalpha.com · Nov 1, 2026

My 'Eye' Is On Tarsus Pharmaceuticals (NASDAQ:TARS)

Tarsus Pharmaceuticals may be undervalued after its pullback, with Xdemvy growth, pipeline upside, and key catalysts ahead. Read the full analysis here on TARS stock.

zacks.com · Oct 27, 2026

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

gurufocus.com · Oct 20, 2026

What First Trust NYSE Arca Biotech (FBT) Bought: Tarsus Leads on Oct. 16

First Trust NYSE Arca Biotechnology Index Fund (FBT) was a net buyer in Friday's session, with 17 positions increased and 13 decreased. The fund's gross trading

Open full news and sentiment

TARS Catalysts FAQ

What are the next catalysts for TARS stock?

TARS's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move TARS stock?

Upcoming events that could move TARS include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could TARS's next earnings report affect the stock?

TARS's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive TARS stock higher?

TARS could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt TARS stock?

TARS could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.